Implementation of this comprehensive strategy with the attainment of improved glycemic control, use of ACE- or AT II1-blockers (RAS-blockade), and statin treatment reduced the risk of nephropathy, progression to end-stage kidney disease, and CV mortality in the STENO-2 trial [91,92]. This evidence concerns the gene ACE and Nephropathy.